{"id":"gzr18","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GZR18 is a recombinant human insulin analog engineered for extended duration of action, allowing once-daily dosing for basal insulin replacement. It is developed by Gan & Lee Pharmaceuticals, a Chinese pharmaceutical company focused on insulin and diabetes therapeutics. The drug aims to improve glycemic control while reducing injection frequency compared to conventional insulin formulations.","oneSentence":"GZR18 is a long-acting basal insulin analog designed to provide sustained glucose control in diabetes.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:49.143Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07493057","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy","status":"NOT_YET_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-04-27","conditions":"Obstructive Sleep Apnea (OSA)","enrollment":140},{"nctId":"NCT07292441","phase":"PHASE3","title":"Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss","status":"RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-01-22","conditions":"Overweight or Obesity","enrollment":500},{"nctId":"NCT07355738","phase":"PHASE1","title":"Bioequivalence Study of GZR18 Injection Before and After CMC Change","status":"RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-01-09","conditions":"Obesity&T2D","enrollment":138},{"nctId":"NCT07128888","phase":"PHASE1","title":"Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection","status":"RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-11-17","conditions":"Obesity or Overweight","enrollment":60},{"nctId":"NCT07150975","phase":"PHASE3","title":"Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects","status":"RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-09-23","conditions":"Obesity/Overweight in Adult","enrollment":420},{"nctId":"NCT06778967","phase":"PHASE3","title":"A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-02-13","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":1100},{"nctId":"NCT06777238","phase":"PHASE3","title":"A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-01-16","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":274},{"nctId":"NCT06728124","phase":"PHASE3","title":"A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2024-12-30","conditions":"Obesity/Overweight","enrollment":630},{"nctId":"NCT07055386","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-08-07","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":90},{"nctId":"NCT07119450","phase":"PHASE1","title":"The Study of [14C] GZR18","status":"COMPLETED","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-05-07","conditions":"Overweight, Obese, Obesity","enrollment":6},{"nctId":"NCT07141030","phase":"PHASE1","title":"Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function","status":"RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-04-11","conditions":"Obesity/Overweight","enrollment":32},{"nctId":"NCT06256562","phase":"PHASE2","title":"A Study of GZR18 Injection in Obese/Overweight Patients","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-06-08","conditions":"Obesity, Overweight","enrollment":340},{"nctId":"NCT07144098","phase":"PHASE1","title":"Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function","status":"RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-08-12","conditions":"Obesity/Overweight","enrollment":24},{"nctId":"NCT06974487","phase":"PHASE1","title":"A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects","status":"NOT_YET_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-05-08","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT06737042","phase":"PHASE2","title":"Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants","status":"NOT_YET_RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2025-02-12","conditions":"Obesity and Overweight","enrollment":285},{"nctId":"NCT06670209","phase":"PHASE1","title":"A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese Subjects","status":"NOT_YET_RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2024-10-30","conditions":"Type 2 Diabetes","enrollment":32},{"nctId":"NCT06554054","phase":"PHASE1","title":"A Study of GZR18 Tablet in Chinese Healthy Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2024-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":92},{"nctId":"NCT06548997","phase":"PHASE1","title":"A Phase I Study of GZR18 Injection in Healthy Subjects","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2021-12-02","conditions":"Type 2 Diabetes, Overweight and Obesity","enrollment":57},{"nctId":"NCT06548945","phase":"PHASE1","title":"A Phase I Study of GZR18 Injection in Obese/Overweight Subjects","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-04-25","conditions":"Overweight and Obesity","enrollment":16},{"nctId":"NCT06256523","phase":"PHASE1, PHASE2","title":"A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2022-06-29","conditions":"Type 2 Diabetes","enrollment":72},{"nctId":"NCT06256536","phase":"PHASE1, PHASE2","title":"A Study of GZR18 Injection in Chinese Obese/Overweight Patients","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2022-07-14","conditions":"Obesity, Overweight","enrollment":60},{"nctId":"NCT06256549","phase":"PHASE2","title":"A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-08-09","conditions":"Type 2 Diabetes","enrollment":272},{"nctId":"NCT05328726","phase":"PHASE1","title":"Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2022-03-08","conditions":"Diabetes Mellitus, Type 2","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GZR18","genericName":"GZR18","companyName":"Gan & Lee Pharmaceuticals.","companyId":"gan-lee-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GZR18 is a long-acting basal insulin analog designed to provide sustained glucose control in diabetes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}